Akeso’s bispecific, Vaxcyte & Woodcock’s quality mindset: BioCentury’s latest podcast

Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters?

Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters? Akeso Inc. (HKEX:9926) is the latest company with a bispecific to impress in a head-to-head study, this one for non-small cell lung cancer. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the latest data from Akeso’s ivonescimab, a VEGFxPD-1 bispecific antibody that went up against Keytruda pembrolizumab in one of its largest indications, first-line non-small cell lung cancer (NSCLC).

The editors also discuss data from  Vaxcyte Inc. (NASDAQ:PCVX) that the infectious disease company parlayed into the year’s largest follow-on financing and a new initiative by FDA veteran Janet Woodcock to bolster quality in biopharmas’ manufacturing.